Program
Anti-PSMA Antibody-drug Conjugate ARX517
Also written as “ARX517” and “JNJ-95298177”.
Its studies are mostly in Prostatic Neoplasms, led by Johnson & Johnson.
Furthest: phase 1, since Sep 12, 20202 company-led studies, 2 open or runningNext primary completion: Dec 31, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 22 open or running | phase 1since Sep 12, 2020 | Sep 12, 2020 | Dec 31, 2026phase 1 · NCT04662580 |
- Named in Johnson & Johnson’s own pipeline as
JNJ-8177 (ARX517)
, phase 1, as of Oct 13, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 12, 2020First study: phase 1 study in Prostatic NeoplasmsFirst studyNCT04662580 · 183 enrolled · United States
- Jul 22, 2025Phase 1 study in Prostatic NeoplasmsNCT07082920 · 140 planned · United States, United Kingdom
Ahead
- Dec 31, 2026Primary completion: phase 1 study in Prostatic NeoplasmsNCT04662580
- Nov 30, 2027Primary completion: phase 1 study in Prostatic NeoplasmsNCT07082920
TargetBeta
“An antibody-drug conjugate (ADC) containing a humanized immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against prostate-specific membrane antigen (PSMA) and site-specifically conjugated to two of the microtubule-disrupting toxin amberstatin (AS269), with potential antineoplastic act…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) containing a humanized immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against prostate-specific membrane antigen (PSMA) and site-specifically ”NCIt, by rule
Other programs on FOLH1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| flotufolastat F 18rule | Bracco | phase 4 | 7 |
| piflufolastatrule | Lantheus | phase 4 | 5 |
| abefolastat tesaroxetan CU-64rule | clarity-pharmaceuticals-ltd | phase 3 | 5 |
| gallium 68 PSMA-11rule | Novartis | phase 3 | 4 |
| Lutetium Lu 177 Ludotadipeprule | futurechem | phase 3 | 3 |
| Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401 | Johnson & Johnson | phase 3 | 2 |
| Lutetium Lu 177 NYM032rule | Norroy Bioscience | phase 3 | 2 |
| actinium AC-225 vipivotide tetraxetan | Novartis | phase 3 | 2 |
| HRS-4357 | Jiangsu HengRui Medicine | phase 3 | 2 |
| zadavotide guraxetan | AstraZeneca | phase 2 | 4 |
| AB-001rule | frontier-biotechnologies-inc | phase 2 | 3 |
| olsutamigrule | Regeneron Pharmaceuticals | phase 2 | 2 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07082920Prostatic Neoplasms · United States, United Kingdom | 1 | Recruiting | Nov 30, 2027 | 140 |
| NCT04662580Prostatic Neoplasms · United States | 1 | Active, not recruiting | Dec 31, 2026 | 183 |
How it is read
Names in the registry
- “ARX517”, 1 entry
- “JNJ-95298177”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.